Lexicon Pharmaceuticals, Inc. (LXRX) Earnings History
Annual and quarterly earnings data from 1999 to 2025
Loading earnings history...
LXRX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
LXRX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 99.4% | -98.2% | -101.1% |
| 2024 | 98.0% | -634.2% | -644.8% |
| 2023 | -4798.0% | -14265.0% | -14710.9% |
| 2022 | -37681.3% | -72489.2% | -73341.0% |
| 2021 | -18371.8% | -29224.8% | -29449.0% |
Download Data
Export LXRX earnings history in CSV or JSON format
Free sign-in required to download data
Lexicon Pharmaceuticals, Inc. (LXRX) Earnings Overview
As of May 8, 2026, Lexicon Pharmaceuticals, Inc. (LXRX) reported trailing twelve-month net income of -$26M, reflecting +77.8% year-over-year growth. The company earned $-0.07 per diluted share over the past four quarters, with a net profit margin of -101.1%.
Looking at the long-term picture, LXRX's historical earnings data spans multiple years. The company achieved its highest annual net income of $130M in fiscal 2019.
Lexicon Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ARDX (-$58M net income, -15.1% margin), CORT ($48M net income, 13.1% margin), INVA ($504M net income, 63.8% margin), LXRX has room to improve margins relative to the peer group. Compare LXRX vs ARDX →
LXRX Earnings vs Peers
Earnings metrics vs comparable public companies
LXRX Historical Earnings Data (1999–2025)
27 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$50M | +74.9% | -$49M | $-0.14 | -101.1% | -98.2% |
| 2024 | -$200M | -13.1% | -$197M | $-0.63 | -644.8% | -634.2% |
| 2023 | -$177M | -73.7% | -$172M | $-0.80 | -14710.9% | -14265.0% |
| 2022 | -$102M | -16.2% | -$101M | $-0.62 | -73341.0% | -72489.2% |
| 2021 | -$88M | -49.8% | -$87M | $-0.61 | -29449.0% | -29224.8% |
| 2020 | -$59M | -145.0% | -$48M | $-0.63 | -244.1% | -199.2% |
| 2019 | $130M | +208.0% | $141M | $1.11 | 40.4% | 43.9% |
| 2018 | -$121M | +6.6% | -$103M | $-1.14 | -190.7% | -163.4% |
| 2017 | -$129M | +8.8% | -$137M | $-1.23 | -142.9% | -151.3% |
| 2016 | -$141M | -2920.7% | -$137M | $-1.36 | -169.7% | -164.6% |
See LXRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LXRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LXRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonLXRX — Frequently Asked Questions
Quick answers to the most common questions about buying LXRX stock.
Is LXRX growing earnings?
LXRX EPS is $-0.07, with earnings growth accelerating to +77.8%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-26M.
What are LXRX's profit margins?
Lexicon Pharmaceuticals, Inc. net margin is -101.1%, with operating margin at -98.2%. Below-average margins reflect competitive or cost pressures.
How consistent are LXRX's earnings?
LXRX earnings data spans 1999-2025. The accelerating earnings trend is +77.8% YoY. Historical data enables comparison across business cycles.